IP Library Granted Patent US 8,629,301
Granted Patent B2
US 8,629,301 · App. 11/718,989 · Granted Jan 14, 2014

Process for the purification of benzphetamine hydrochloride

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,629,301
App. No.
11/718,989
Granted
Jan 14, 2014
Kind
B2
Abstract

The present invention relates to the economical and separation of benzphetamine hydrochloride and methamphetamine by liquid extraction. An extraction process employing a suitable organic solvent and water at a pH in the range of from about 6 to about 8 provides excellent removal of the methamphetamine by dissolution in the water phase while the benzphetamine dissolves in the organic phase. Simple separation of the two phases results in separation of the two amines.

Claims (36)

1. A process for removing methamphetamine hydrochloride from crude benzphetamine hydrochloride which comprises subjecting the said crude hydrochlorides to liquid extraction with an organic solvent and water at a pH in the range of from about 6 to 8 wherein the benzphetamine hydrochloride is converted to a base and separates into the organic phase and the methamphetamine hydrochloride remains in the aqueous phase.

2. The process of claim 1 wherein the pH is in the range of from about 6 to about 6.5.

3. The process of claim 1 wherein the organic solvent selected from the group consisting of benzene, toluene, xylene, hexane, heptane, cyclohexane.

4. The process of claim 3 wherein organic solvent is toluene.

5. The process of claim 1 wherein the pH of the water is adjusted with an acid.

6. The process of claim 5 wherein the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, and acetic acid.

7. The process of claim 6 wherein the acid is hydrochloric acid.

8. The process of claim 1 wherein the pH of the water is adjusted with a base.

9. The process of claim 8 wherein the base is selected from the group consisting of alkali metal carbonates, alkali metal bicarbonates and alkali metal hydroxides.

10. The process of claim 9 wherein the base is sodium carbonate.

11. A process for removing methamphetamine from crude benzphetamine hydrochloride which comprises the steps of:

A. subjecting the crude benzphetamine hydrochloride to liquid extraction with an organic solvent and water at a pH in the range of from about 6 to 8;

B. separating the water containing the methamphetamine base from the organic solvent containing benzphetamine base, then converting the benzphetamine base to the hydrochloride salt; and

C. separating the benzphetamine hydrochloride salt from the organic solvent.

12. The process of claim 11 wherein step C is performed by filtration of the benzphetamine hydrochloride salt from the organic solvent.

13. The process of claim 11 wherein step C is performed by extracting benzphetamine hydrochloride salt from the organic solvent.

14. The process of claim 11 wherein the pH of the water in step A is in the range of from about 6 to about 6.5.

15. The process of claim 11 wherein the organic solvent selected from the group consisting of benzene, toluene, xylene, heptane and cyclohexane.

16. The process of claim 15 wherein organic solvent is toluene.

17. The process of claim 11 wherein the pH of the water is adjusted with an acid.

18. The process of claim 17 wherein the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid and acetic acid.

19. The process of claim 18 wherein the acid is hydrochloric acid.

20. The process of claim 11 wherein the pH of the water is adjusted with a base.

21. The process of claim 20 wherein the base is selected from the group consisting of alkali metal hydroxides, alkali metal carbonates and alkali metal bicarbonates.

22. The process of claim 21 wherein the base is selected from the group consisting of sodium hydroxide, potassium hydroxide; sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate.

23. The process of claim 22 wherein the base is sodium carbonate.

24. A process for removing methamphetamine hydrochloride from crude benzphetamine base which comprises subjecting crude methamphetamine base and the benzphetamine base to liquid extraction with an organic solvent and water at a pH in the range of from about 6 to 8 wherein the benzphetamine base remains in the organic phase and the methamphetamine is converted to a salt and remains in the aqueous phase.

25. The process of claim 24 wherein the pH is in the range of from about 6 to about 6.5.

26. The process of claim 24 wherein the organic solvent selected from the group consisting of benzene, toluene, xylene, hexane, heptane, cyclohexane.

27. The process of claim 26 wherein organic solvent is toluene.

28. The process of claim 24 wherein the pH of the water is adjusted with an acid.

29. The process of claim 28 wherein the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, and acetic acid.

30. The process of claim 29 wherein the acid is hydrochloric acid.

31. The process of claim 24 wherein the pH of the water is adjusted with a base.

32. The process of claim 31 wherein the base is selected from the group consisting of alkali metal carbonates, alkali metal bicarbonates and alkali metal hydroxides.

33. The process of claim 32 wherein the base is sodium carbonate.

Assignments (1)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →